A Single Arm Phase II Study Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in Patients With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs Camptothecin (Primary) ; Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 17 Apr 2019 Planned End Date changed from 30 Jun 2020 to 30 Jun 2021.
- 26 Mar 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 29 Mar 2019 to 1 Apr 2019.
- 23 Mar 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Mar 2019 to 29 Mar 2019.